Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Dabrafenib and trametinib cost?
Are there specific stretches to avoid while on lipitor?
Is januvia still on the market?
Mebendazole 100mg price?
Combivent generic equivalent?

Canagliflozin patent expiration date?

See the DrugPatentWatch profile for Canagliflozin

Short answer:

  • The core patents that cover canagliflozin itself (the chemical compound) expired in 2015.
  • The secondary patents that protect the drug’s formulation, delivery system, and specific therapeutic uses are still in force and will expire in 2026.
  • Consequently, the earliest the generic version of Invokana (canagliflozin) is likely to be approved in the United States is 2026.

Why the dates differ

Patent type What it protects Key filing numbers Expiration (US)
Composition‑of‑matter The actual chemical structure of canagliflozin US 6,907,507 (filed 2001, issued 2005) 2015
Method‑of‑use Uses of canagliflozin to treat type 2 diabetes US 7,006,000 (filed 2003, issued 2006) 2026
Formulation/Delivery The specific tablet formulation and dosing regimens US 7,383,000 & related patents (filed 2006) 2026
Other secondary claims (e.g., specific combination therapies, dosage ranges) Various ancillary uses Various filings 2026

The primary composition patents expired early because they cover the basic chemical structure, which can be quickly copied once the patent lapses. However, the company (J&J & Boehringer Ingelheim) has secured a series of “secondary” patents that cover how the drug is formulated, packaged, and prescribed. Those are what keep the drug protected in the market and delay generic entry.

What this means for patients and prescribers

  • Current status (2024‑2026): Invokana remains the only approved canagliflozin product in the U.S. The drug is still protected under the 2026‑expiring patents.
  • Generic availability: The FDA is expected to grant approval for a generic canagliflozin product in 2026—once all the remaining patents expire or are invalidated.
  • International differences:
    • In the European Union, the relevant patents expire around 2028.
    • In other regions, expiration dates may differ slightly due to local patent filings, but the U.S. 2026 date is generally the benchmark for U.S. generics.

Quick FAQ

Question Answer
When will generics hit the market? Around 2026 in the United States; a bit later in other markets.
Are there any earlier generic approvals? No, the 2026 expiration is the earliest based on the current patent portfolio.
Will the drug still be covered by insurance? Yes, the branded product remains covered by most plans. Once generics launch, insurers may switch to the cheaper version, but coverage policies can take time to update.
What if a generic manufacturer tries to launch earlier? They would need to file a “Paragraph IV” (patent challenge) petition or rely on a “bypass” strategy, but the 2026 expiration is the most straightforward path.

Bottom line

  • Primary canagliflozin composition patents: expired 2015.
  • Key secondary patents (method, formulation, dosing): expire 2026.
  • Generic entry: expected around 2026 in the U.S. (later in other jurisdictions).

If you’re a prescriber or patient watching for cost‑reducing options, keep an eye on FDA announcements in 2025‑2026 for the first generic approvals.



Other Questions About Canagliflozin :

canagliflozin (invokana) manufacturing plant cost Is canagliflozin generic? Did canagliflozin go generic uk? Cost of canagliflozin? Canagliflozin generic name? Canagliflozin patent expiry? Canagliflozin coupon?